NeuroThera Secures U.S. Patent for Cannabinoid-Enhanced Antimicrobial Platform Targeting MRSA and Antibiotic Resistance
核心洞察
NeuroThera Labs has received a U.S. patent for its proprietary combination of antimicrobials (搜索) and cannabinoids, including THC and CBD, designed to enhance existing antibiotics (搜索) against resistant bacterial strains.
The patented technology demonstrated in preclinical studies the ability to restore effectiveness of antibiotics (搜索) against methicillin-resistant Staphylococcus aureus (搜索) (MRSA (搜索)), which caused approximately 130,000 deaths worldwide in 2021.
The platform combines decades-old antibiotics (搜索) with cannabinoids to potentially eliminate the need for constant development of new antibiotics while leveraging proven safety profiles.
NeuroThera Labs Inc. (搜索), a clinical-stage pharmaceutical company and majority-owned subsidiary of SciSparc Ltd., has secured a U.S. patent from the United States Patent and Trademark Office (搜索) for its proprietary combination of antimicrobials (搜索) and cannabinoids. The patent covers innovative compositions and methods specifically designed to enhance the efficacy of existing antibiotics (搜索) against resistant bacterial strains, particularly targeting the growing threat of antimicrobial resistance (搜索).
Novel Cannabinoid-Antibiotic Combination Platform
The patented technology combines well-established antibiotics (搜索)—many of which have been on the market for decades—with cannabinoids such as Δ⁹-Tetrahydrocannabinol (搜索) (THC) and Cannabidiol (CBD), and in certain embodiments, N-acylethanolamines like palmitoylethanolamide (PEA). This synergistic approach demonstrated in preclinical studies enhances antimicrobial activity, potentially restoring the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens, such as Methicillin-resistant Staphylococcus aureus (搜索) (MRSA (搜索)).
When administered in combination with cannabinoids, the platform leverages the extensive long-term safety data of these antibiotics (搜索) to help minimize risk, potentially offering an effective, safe, and affordable therapeutic solution. The patent family is based on preclinical studies conducted to evaluate the antimicrobial effects of cannabinoids when combined with antibiotics in well-established, regulatory-compliant models.
Addressing the MRSA Crisis
MRSA (搜索) remains a leading global threat, evading multiple antibiotic classes. According to a comprehensive analysis in The Lancet (September 2024), MRSA directly caused approximately 130,000 deaths worldwide in 2021—more than double the approximately 57,000 deaths in 2019—and showed the largest increase in attributable mortality among resistant pathogens. Bacterial antimicrobial resistance (搜索) (AMR) overall directly caused 1.14 million deaths and was associated with 4.71 million deaths in 2021 worldwide, with a global median methicillin resistance rate of 27.1% in S. aureus bloodstream infections in 2023, according to the WHO Global Antimicrobial Resistance Surveillance Report, 2025.
The crisis has been further evidenced by a 30% rise in healthcare-acquired infections in the U.S. over recent years, highlighting the critical need for innovative solutions that enhance existing antibiotics (搜索)' efficacy while improving safety.
Market Implications and Industry Challenges
The global antibiotics (搜索) market is projected to reach approximately $58 billion in 2026, according to a report published by Mordor Intelligence entitled "Antibiotics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)," driven by the escalating challenge of antimicrobial resistance (搜索).
The "antimicrobial-sparing" effect shown in preclinical studies using NeuroThera's proprietary combination may eliminate the constant requirements for new antibiotics (搜索) to combat resistant microbial strains, helping mitigate serious side effects such as resistance development, organ toxicity, and gastrointestinal issues, all while capitalizing on the proven safety profiles of long-marketed antibiotics.
According to the World Health Organization, pharmaceutical companies have increasingly shied away from developing new antibiotics (搜索) due to a combination of prolonged development timelines, high costs, and the swift emergence of bacterial resistance, which collectively undermine profitability. The process of bringing a novel antibiotic to market typically spans 10 to 15 years, involving rigorous clinical trials and regulatory hurdles that drive up expenses. Compounding this, bacteria can develop resistance to new antibiotics within just a few years of introduction, leading to restricted usage to preserve efficacy and resulting in limited sales potential compared to chronic disease treatments.
Strengthened Intellectual Property Portfolio
This patent grant in the United States joins previously granted patents for the same family in the U.S. and Europe, further strengthening the global intellectual property protection of NeuroThera's proprietary antimicrobial-potentiating platform. The expanded patent protection provides a stronger foundation for the company's development and potential commercialization efforts in addressing antibiotic resistance (搜索).
NeuroThera Labs Inc. (搜索) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. The company operates as a majority-owned subsidiary of SciSparc Ltd., which holds approximately 75% controlling interest.